C12N 2740/15063
By chemical treatment
Official title: by chemical treatment
C12N2740/15063 (By chemical treatment) appears on 5 US grants and 12 published applications in this corpus.
Search patents in C12N- Granted patents
- 5
- Published applications
- 12
- Assignees
- 6
- Inventors
- 25
- Latest grant
- 24 Mar 2015
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 2005 | 0 | 1 |
| 2006 | 0 | 0 |
| 2007 | 0 | 0 |
| 2008 | 1 | 1 |
| 2009 | 0 | 2 |
| 2010 | 0 | 1 |
| 2011 | 0 | 2 |
| 2012 | 2 | 0 |
| 2013 | 0 | 0 |
| 2014 | 0 | 1 |
| 2015 | 2 | 2 |
| 2016 | 0 | 0 |
| 2017 | 0 | 0 |
| 2018 | 0 | 0 |
| 2019 | 0 | 0 |
| 2020 | 0 | 0 |
| 2021 | 0 | 0 |
| 2022 | 0 | 1 |
| 2023 | 0 | 0 |
| 2024 | 0 | 0 |
| 2025 | 0 | 1 |
By publication year.
Recent patents
- Methods for treating spinal muscular atrophy24 Mar 2015US 8,986,935 B2PTC Therapeutics, Inc.
- Screening assays for compounds that modulate programmed ribosomal frameshifting13 Jan 2015US 8,932,818 B2PTC Therapeutics, Inc.
- Inactivated influenza virus compositions2 Oct 2012US 8,278,083 B2The United States of America, as represented by the Secretary, Department of Health and Human Services
- Cellular and viral inactivation18 Sep 2012US 8,268,602 B2The United States of America, as represented by the Secretary, Department of Health and Human Services
- Modified viral particles with immunogenic properties and reduced lipid content5 Aug 2008US 7,407,662 B2Lipid Sciences, Inc.
- Nucleic Acid Molecule, Vector, Recombinant Cells, and Drug for Treating Central Nervous System Disease18 Dec 2025US 2025/0381296 A1JCR Pharmaceuticals Co., Ltd.
- Method for Generation of Genetically Modified T Cells14 Jul 2022US 2022/0220504 A1
- Methods for treating viral infections3 Dec 2015US 2015/0344877 A1PTC Therapeutics, Inc.
- Methods for treating spinal muscular atrophy8 Oct 2015US 2015/0283115 A1PTC Therapeutics, Inc.
- Modified viral particles with immunogenic properties and reduced lipid content useful for treating and preventing infectious diseases20 Feb 2014US 2014/0050763 A1Eli Lilly and Company
Most cited
By later US patents
- Modified viral particles with immunogenic properties and reduced lipid content4US 7,407,662 B2Lipid Sciences, Inc. · 2008
- Cellular and viral inactivation1US 8,268,602 B2The United States of America, as represented by the Secretary, Department of Health and Human Services · 2012
- Inactivated influenza virus compositions1US 8,278,083 B2The United States of America, as represented by the Secretary, Department of Health and Human Services · 2012